Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHalma Regulatory News (HLMA)

Share Price Information for Halma (HLMA)

Share Price is delayed by 15 minutes
Get Live Data
4,664.00    -214.00 (-4.39%)
Bid:
4,682.00
Ask:
4,686.00
Spread: 4.00 (0.085%)
Market Cap: £17.62b
HLMA Live PriceLast checked at - London Stock Exchange

Intraday Halma Share Chart

Directorate Change

30 Jan 2024 07:00

RNS Number : 3498B
Halma PLC
30 January 2024
 

Halma plc ("Halma" or "Company")Directorate Change

 

Halma, the FTSE 100 global group of life-saving technology companies, today announces the appointment of Giles Kerr as an independent non-executive Director, with effect from 1 February 2024. Giles will also be a member of Halma's Audit, Remuneration and Nomination Committees.

 

Giles brings a wealth of experience gained across a variety of roles in life sciences, technology and industrial businesses. Giles has a particularly strong background in driving strategic business growth as well as extensive M&A experience. He is currently Chair of PayPoint plc and was Senior Independent Director & Audit Committee Chair at Abcam plc, until it was acquired by Danaher in December 2023.

 

His executive career included senior financial roles at Arthur Andersen (leading to his appointment as National Partner), Amersham plc (latterly as Group Finance Director) and as Finance Director at Oxford University Innovation. Since 2007, Giles has held a number of non-executive director roles including Elan Corporation, Victrex plc, BTG plc, Oxford Sciences Innovation plc, Arix Bioscience plc and Senior plc.

 

Roy Twite, non-executive Director, who has served for nine years on the Board, will step down as a Director on 7 June 2024.

 

Dame Louise Makin, Chair, commented:"I am delighted that Giles is joining the Halma Board. His extensive executive and non-executive experience, particularly in the life sciences and technology sectors, will bring valuable insights and perspectives to the Board.

 

I would like to thank Roy for his valuable contribution to Halma, and particularly the support that he has given to me and the Board to ensure an orderly transition and onboarding of recent executive and non-executive Directors"

 

There are no further details to be disclosed for Giles Kerr under Listing Rule 9.6.13R.

 

 

For further information, please contact:

Halma plcMarc Ronchetti, Group Chief ExecutiveSteve Gunning, Chief Financial Officer

Charles King, Head of Investor Relations

Clayton Hirst, Director of Corporate Affairs

+44 (0)1494 721 111

+44 (0)7776 685948

+44 (0)7834 796 013

MHPOliver Hughes/Rachel Farrington/Ollie Hoare

+44 (0)20 3128 8100

A copy of this announcement, together with other information about Halma, may be viewed on its website: www.halma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAKZGFMVGFGDZG
Date   Source Headline
28th May 20267:15 amRNSExecutive Board changes
13th Apr 20267:00 amRNSAcquisition
12th Mar 20267:00 amRNSTrading Update
13th Jan 20269:18 amRNSDirector/PDMR Shareholding
9th Jan 20261:26 pmRNSDirector/PDMR Shareholding
9th Jan 20267:00 amRNSAcquisition
5th Dec 20257:00 amRNSAcquisition
20th Nov 20257:00 amRNSHalf Year Results
1st Oct 20252:00 pmRNSDirector/PDMR Shareholding
26th Sep 202510:19 amRNSDirector/PDMR Shareholding
25th Sep 20257:00 amRNSTrading Update
26th Aug 20257:00 amRNSAcquisition
24th Jul 20252:15 pmRNSResult of AGM
30th Jun 202511:30 amRNSDirector/PDMR Shareholding
25th Jun 20258:30 amRNSAGM - Revised Form of Proxy
24th Jun 20259:20 amRNSDirector/PDMR Shareholding
20th Jun 20255:15 pmRNSAnnual Financial Report
18th Jun 20254:47 pmRNSDirector/PDMR Shareholding
12th Jun 20257:00 amRNSFull Year Results
16th May 20257:00 amRNSDirectorate Change
28th Mar 20251:10 pmRNSDirector/PDMR Shareholding
21st Mar 20252:00 pmRNSDirectorate Change
13th Mar 20257:00 amRNSTrading Update
28th Feb 20254:29 pmRNSDirector/PDMR Shareholding
14th Jan 20252:05 pmRNSDirector/PDMR Shareholding
8th Jan 20257:00 amRNSAppointment of Chief Financial Officer
28th Nov 202410:04 amRNSDirector/PDMR Shareholding
22nd Nov 20243:30 pmRNSDirector/PDMR Shareholding
22nd Nov 20243:26 pmRNSDirector/PDMR Shareholding
21st Nov 20247:00 amRNSHalf Year Results
18th Nov 20247:00 amRNSAcquisition
6th Nov 20242:34 pmRNSDirector Declaration
2nd Oct 20249:20 amRNSDirector/PDMR Shareholding
26th Sep 20247:00 amRNSTrading Update
24th Sep 20249:45 amRNSDirector/PDMR Shareholding
3rd Sep 20249:15 amRNSPDMR Shareholding
25th Jul 20241:51 pmRNSResult of AGM
24th Jul 20249:15 amRNSDirector/PDMR Shareholding
17th Jul 202412:46 pmRNSDirector Declaration
1st Jul 20249:51 amRNSDirector/PDMR Shareholding
27th Jun 20247:00 amRNSAcquisition
25th Jun 20243:00 pmRNSDirector/PDMR Shareholding
24th Jun 20245:26 pmRNSAnnual Financial Report
13th Jun 20247:00 amRNSFull Year Results
1st May 20247:00 amRNSAcquisition
19th Mar 20243:53 pmRNSDirector/PDMR Shareholding
14th Mar 20247:00 amRNSTrading Update
4th Mar 20247:00 amRNSAcquisition
21st Feb 20244:17 pmRNSDirector/PDMR Shareholding
30th Jan 20247:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.